A plain-English guide to multiple sclerosis — what it is, how it’s diagnosed, and how it’s treated in Australia in 2026. Medically reviewed by a Sydney MS subspecialist.
Multiple sclerosis is an autoimmune condition in which the immune system attacks the insulation around nerve fibres in the brain, spinal cord and optic nerves. There is no cure, but modern treatment makes it highly treatable.
Tap or hover any dotted-underlined term for a plain-English definition.
Just been told you might have MS? Take a breath — you almost certainly have time to make calm, informed decisions. There’s a step-by-step page written for you — what to do now →
Already living with MS and want to move your care to CURA? Meet the MS team → — subspecialist neurologist, on-site DMT injections, and no public-hospital infusion wait.
A GP referring a patient? For referring GPs →
Multiple sclerosis (MS) is an autoimmune condition affecting the central nervous system — your brain, spinal cord, and optic nerves. The immune system mistakenly attacks myelin, the protective insulation around nerve fibres.
Think of myelin as the plastic coating on an electrical cable. When myelin is damaged, signals between brain and body slow down or get blocked, different parts of the nervous system can be affected (producing different symptoms), and the nerve fibre underneath can become damaged over time.
Key facts: approximately 25,600 Australians are reported to live with MS (MS Australia); it is roughly two to three times more common in women than men; most people are diagnosed between ages 20 and 40 (though it can begin earlier or later); MS is not contagious, not directly inherited, and not caused by anything you did.
MS symptoms are highly variable. You may have some, none, or different symptoms from those listed here. Many of these symptoms are also caused by conditions that are not MS — only a specialist assessment with MRI can confirm a diagnosis.
A small rise in body temperature — from heat, exercise or fever — can temporarily worsen MS symptoms. This is called a pseudorelapse (or Uhthoff phenomenon): it is not a true new attack on the nervous system, and it resolves once temperature returns to normal. See Living with MS for practical heat-management tips.
There is no single cause. MS develops when several factors come together in someone who is genetically susceptible.
The immune system mistakenly targets myelin and nerve fibres, producing the inflammatory lesions that show up on MRI.
Large studies published in the early 2020s have established a strong association between past EBV infection and MS — almost everyone with MS has a history of EBV. EBV is now considered a key triggering factor, although most people who catch EBV do not go on to develop MS. Vaccine candidates targeting EBV are in clinical trials and may eventually become a prevention tool; we will discuss them with you if and when they reach approval.
MS is not inherited in a simple way. Having a first-degree relative with MS raises your lifetime risk to roughly 3–5% (compared with about 0.1% in the general population). Most people with MS have no family history, and routine screening of relatives is not recommended.
There is no single test for MS. The diagnosis is built from your history, a neurological examination, and an MRI of the brain and spinal cord — sometimes with a lumbar puncture if the MRI alone is inconclusive. With a recent MRI in hand, MS can often be confirmed in one or two visits over two to four weeks.
The framework we use is the international McDonald criteria, which look for evidence of MS-type lesions occurring at different times and in different locations in the central nervous system.
Confirming MS responsibly takes precedence over confirming it quickly, and ruling out other conditions is part of the process.
The Australian approach to MS has shifted significantly over the last decade. Where treatment was once a stepped escalation starting with weaker injectable medications, current best practice for most people with active relapsing MS is to start a high-efficacy disease-modifying therapy early — often as the first treatment.
The reasoning: high-efficacy DMTs reduce relapse rates and MRI lesion activity dramatically, and earlier control protects long-term brain health. This “high-efficacy early” approach — framed internationally under the MS Brain Health “time matters” initiative — is the current direction of Australian neuroimmunology practice. Your neurologist will discuss the right approach for your particular pattern of disease.
The widely-used international yardstick is NEDA-3 (No Evidence of Disease Activity), which tracks three components. Whether or not your specialist uses that exact term in your appointment, the same three components are what they will be tracking at follow-up:
If your current therapy is not delivering on these three measures, that is a reason to discuss switching to a more effective option — not a reason to give up.
A range of PBS-subsidised DMTs is available, broadly grouped into high-efficacy options (anti-CD20 antibodies — ocrelizumab, ofatumumab and ublituximab; natalizumab; cladribine), moderate-efficacy options (S1P modulators, fumarates, older injectables), and a small number reserved for highly active or treatment-refractory disease. You don’t need to memorise the list — your neurologist works through this with you, based on your disease pattern, planning around pregnancy if relevant, and what you’re willing to take (injection vs tablet). The prescribing decision and PBS authority paperwork are completed during your specialist appointment — no separate hospital co-sign or external referral delay.
JC virus (JCV) and PML risk. JC virus is a common, usually harmless virus that most adults have been exposed to. In people on long-term natalizumab who are JCV-antibody positive, there is a small but real risk of progressive multifocal leukoencephalopathy (PML). Because of this, our approach is risk-avoidance first: JCV antibody status is checked before starting natalizumab, and for patients who are JCV-positive we generally recommend an alternative high-efficacy DMT rather than natalizumab. For JCV-negative patients on natalizumab, antibody status is rechecked periodically alongside surveillance MRI; if seroconversion occurs, we move to switch therapy promptly rather than continue and watch.
On the horizon. Bruton’s tyrosine kinase (BTK) inhibitors such as tolebrutinib and evobrutinib are in late-stage clinical trials; we will discuss them with you if and when they become PBS-listed.
Your neurologist’s recommendation will weigh:
A true MS relapse is a new neurological deficit (or clear worsening of an existing one) that is objectively documented on neurological examination by your treating clinician. Specifically, a relapse:
A new sensation that comes and goes during a hot day or while you’re unwell, then settles, is most likely a pseudorelapse — temporarily impaired nerve conduction in pre-existing MS lesions, not a true new attack. Treat the trigger (cool down, treat the infection) and symptoms usually resolve. If you’re unsure, contact us — that is exactly the call we want you to make.
A pattern of frequent or severe relapses on your current DMT is a signal that we should review whether to escalate to a more effective therapy — not a reason to give up on treatment.
Most people with MS continue to work, travel, raise families, exercise, and pursue what matters to them. Modern treatment makes this the norm, not the exception.
If heat reliably worsens your symptoms (Uhthoff phenomenon / pseudorelapse):
Where possible, complete routine vaccinations — including the annual influenza vaccine and any indicated live vaccines (MMR, varicella, herpes zoster) — before starting an immunosuppressive DMT. Interferon-beta and glatiramer acetate are not immunosuppressive, so vaccination timing is more flexible on those. Once you are on an immunosuppressive DMT, inactivated vaccines remain safe and recommended; live vaccines are usually avoided.
Typical follow-up includes:
Routine bloods between specialist visits can be coordinated with your GP. We send a full letter to your GP after each visit so your team is kept informed.
If you are planning pregnancy, are pregnant, or are breastfeeding, talk to us before making any change to your DMT. Pregnancy planning in MS is highly individualised — the right approach depends on which DMT you are on, how active your disease is, and your family-planning timeline.
Some DMTs can be continued up to conception, and in selected cases into pregnancy itself — natalizumab is one example, where ongoing therapy is sometimes the safer choice for women with active disease. Other DMTs need to be stopped well in advance with a defined washout period before conception. Breastfeeding compatibility also varies between drug classes.
Your neurologist will work with you to plan the timing of any DMT change against your family-planning intentions. The general rule is to plan ahead together rather than to act on your own — uncontrolled relapse risk in the postpartum period is real, and many DMTs can be continued or strategically timed around conception.
If you find yourself unexpectedly pregnant on a DMT, contact us as soon as possible for advice — do not stop your medication on your own. We will review your specific therapy, discuss what is safe to continue, and arrange any monitoring or change of plan.
A first MS consultation usually takes 45–60 minutes.
Specialist consultations attract Medicare rebates; out-of-pocket fees vary by appointment type — please ask reception when booking. PBS-listed DMTs (including the high-efficacy options above) are covered with the standard PBS patient co-payment. MRI is generally covered by Medicare with a specialist referral but may have a gap fee depending on the radiology provider. People with significant MS-related disability may be eligible for NDIS support; we can provide medical evidence and coordinate with your GP. For current fees and availability, please call our reception or use the online booking page.
There is currently no cure for MS, but it is highly treatable. Modern disease-modifying therapies dramatically reduce relapse frequency, slow progression, and protect long-term brain health. Most people on appropriate treatment live full, active lives.
Relapsing-remitting MS (about 85% of new diagnoses) features distinct relapses with partial or full recovery between them. Primary progressive MS (10–15%) shows steady worsening from onset without distinct relapses. Treatment options differ; your neurologist tailors therapy to your phenotype.
Yes. CURA Specialists administers both ocrelizumab and natalizumab on-site at our Drummoyne and Nepean / Penrith clinics — ocrelizumab every 6 months, natalizumab as a subcutaneous injection every 4 weeks — supervised by our neurology team. This avoids the wait times typical of public hospital day-unit infusions.
Yes. CURA’s neurologists see MS patients at both Drummoyne and Nepean / Penrith, and the team includes clinicians with subspecialty training in Multiple Sclerosis and neuroimmunology. Both clinics offer on-site DMT administration, including ocrelizumab and natalizumab.
Yes. CURA’s MS service includes neurologists who are PBS-authorised prescribers for ocrelizumab, ofatumumab, ublituximab, natalizumab, cladribine and the other current PBS-listed disease-modifying therapies. Authority applications are completed during your appointment — no separate hospital co-sign delay.
NEDA-3 — No Evidence of Disease Activity — is a widely used international yardstick for MS treatment success across three components: no relapses in the past year, no new or enlarging MRI lesions, and no worsening on standardised neurological examination confirmed to persist for at least 3 months. Whether or not the term is used in your appointment, your specialist will be tracking the same components at follow-up. If your therapy is not delivering on these, that is a reason to discuss switching.
Diagnosis follows the international McDonald criteria and combines clinical history, neurological examination, and MRI of the brain and spinal cord. In some cases a lumbar puncture, looking for oligoclonal bands in the cerebrospinal fluid, supports diagnosis where MRI alone is not definitive. There is no single blood test for MS.
JC virus is a common, usually harmless virus most adults have been exposed to. In people on long-term natalizumab who are JCV-antibody positive, there is a small but real risk of progressive multifocal leukoencephalopathy (PML), a serious brain infection. Our approach is risk-avoidance first: JCV antibody status is checked before starting natalizumab, and patients who are JCV-positive are generally steered to an alternative high-efficacy DMT rather than natalizumab. For JCV-negative patients on natalizumab, antibody status is rechecked periodically alongside surveillance MRI — and if someone seroconverts, treatment is switched promptly rather than continued and watched.
MS itself does not usually harm pregnancy. Pregnancy often reduces relapse rates, although risk can increase in the months after giving birth. Pregnancy planning in MS is highly individualised — some DMTs can be continued up to (and in selected cases into) pregnancy, including natalizumab, while others need a planned washout before conception. Please plan ahead with your neurologist rather than making changes on your own. If you find yourself unexpectedly pregnant on a DMT, contact us as soon as possible for advice.
MS Australia operates a free MS Nurse Helpline on 1800 042 138. It is staffed by experienced MS nurses and is a useful first call for symptom questions, education, or support between specialist appointments. CURA does not currently have an in-house MS nurse but works with the helpline and your GP for between-visit support.
It depends on what investigations are already complete. With a recent MRI in hand, diagnosis can sometimes be confirmed in a single visit. More often it takes two visits over two to four weeks — initial assessment, the relevant additional imaging or lumbar puncture, then a review to confirm diagnosis and discuss treatment.
Call our reception as soon as possible and flag “possible MS relapse” so it can be prioritised for early specialist assessment. If your symptoms are severe (sudden weakness, vision loss, loss of bladder or bowel control), go to the emergency department of your nearest hospital and ask them to contact us.
CURA Medical Specialists — specialist MS care in Drummoyne and Nepean / Penrith, Sydney. Book a consultation · For referring GPs
